Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Nkarta, Inc.

NASDAQ: NKTX · Life Sciences · 4 alerts · CIK 1787400

Share price
$1.21Close, Nov 16
Market cap
$86.8M
Shares outstanding
71.7MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Nkarta, Inc. filings on SEC EDGAR ↗

4:40 PM ET 10-Q
Financial Results

Nkarta Q3 2026 Results: Net Loss of $33.3M, Loss Widens

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on CAR NK-cell therapies, specifically NKX019 for autoimmune diseases. As of September 30, 2026, the company remains pre-revenue with significant accumulated losses and expects to continue incurring losses as it advances its novel therapeutic platform through clinical development.

Key figure
Net loss $33.3M
4:37 PM ET 8-K
Financial Results

Nkarta Financial Results

Nkarta, Inc. reported third quarter 2026 financial results, highlighting a net loss of $33.3 million and a cash position of $216.0 million. The company announced that initial clinical data for its NKX019 cell therapy in myositis and systemic sclerosis will be presented at the ACR Convergence 2026 conference in November. Management expects its current cash runway to fund operations into 2029.

Term
Q3 2026

“NKX019 is advancing in our two lead indications, myositis and systemic sclerosis. We’re delighted to have been selected to present our initial clinical data in two oral presentations and one poster presentation at ACR Convergence 2026 in Orlando. We believe that the safety profile of engineered CAR-NK cells could broaden cell therapy access to reach far more patients. With off-the-shelf availability and outpatient dosing at a growing network of community-based sites, our program is designed to deliver on that potential.”

Paul J. Hastings, Chief Executive Officer of Nkarta

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.